Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21208463 | 0.81 | HPGD (0.43) | KDM4EALDH1A1MAPTNPSR1GAA | |
| SCHEMBL18042578 | 0.76 | KDM4E (0.49) | KDM4EALDH1A1MAPTGAAGLA | |
| SCHEMBL6310567 | 0.75 | KDM4E (0.50) | KDM4EALDH1A1MAPTNPSR1GAA | |
| SCHEMBL15579203 | 0.74 | KDM4E (0.56) | KDM4EALDH1A1MAPTNPSR1GAA | |
| SCHEMBL17255009 | 0.74 | KDM4E (0.54) | KDM4EALDH1A1MAPTNPSR1GAA | |
| SCHEMBL17255069 | 0.74 | KDM4E (0.57) | KDM4EALDH1A1MAPTGAAPOLB | |
| SCHEMBL17255029 | 0.74 | HRH3 (0.52) | KDM4EALDH1A1MAPTNPSR1GAA | |
| SCHEMBL31403195 | 0.74 | TSHR (0.40) | KDM4EALDH1A1MAPTNPSR1GAA | |
| SCHEMBL17255024 | 0.74 | TSHR (0.40) | KDM4EALDH1A1MAPTNPSR1GAA | |
| SCHEMBL29587846 | 0.73 | KDM4E (0.51) | KDM4EALDH1A1MAPTNPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
| US-20210094952-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2021-04-01 | — | — | US | disclosed |
| US-20200361937-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
| US-10745403-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10590134-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10442801-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2019-10-15 | — | — | US | disclosed |
| US-9951066-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3140305-B1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | PIMERA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2018-03-22 | — | — | US | disclosed |
| US-20170334905-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2017-11-23 | — | — | US | disclosed |
| EP-3219716-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | Pimera, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9512123-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512123-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160326176-A1 | Novel Compositions, Uses and Methods for Making Them | PIMERA, INC | 2016-11-10 | — | — | US | disclosed |
| US-20160326176-A1 | Novel Compositions, Uses and Methods for Making Them | PIMERA, INC | 2016-11-10 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
| WO-2015172123-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | HADDACH MUSTAPHA (US) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326176-A1 | Novel Compositions, Uses and Methods for Making Them | BAX, CASP3, BCL2 | KDM4E 2839/4885ALDH1A1 3544/4885MAPT 4105/4885 |
| US-10590134-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | KDM4E 2323/4885ALDH1A1 3165/4885MAPT 4126/4885 |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | KDM4E 2839/4885ALDH1A1 3544/4885MAPT 4105/4885 |
| US-10745403-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | KDM4E 2323/4885ALDH1A1 3165/4885MAPT 4126/4885 |
| US-20200361937-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | KDM4E 2839/4885ALDH1A1 3544/4885MAPT 4105/4885 |
| US-20170334905-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | KDM4E 2839/4885ALDH1A1 3544/4885MAPT 4105/4885 |
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, CASP7 | KDM4E 2459/4885ALDH1A1 2282/4885MAPT 4128/4885 |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | KDM4E 2839/4885ALDH1A1 3544/4885MAPT 4105/4885 |
| US-20210094952-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | KDM4E 2839/4885ALDH1A1 3544/4885MAPT 4105/4885 |
| US-10442801-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | KDM4E 2323/4885ALDH1A1 3165/4885MAPT 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.